Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
about
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicityThe clinical development of obinutuzumab for the treatment of follicular lymphoma.IgE-based immunotherapy of cancer: challenges and chances.Lepidopteran cells, an alternative for the production of recombinant antibodies?Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panelPoly(ethylene glycol)-Lipid-Conjugated Antibodies Enhance Dendritic Cell Phagocytosis of Apoptotic Cancer Cells.Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.New antibody drug treatments for lymphoma.Potential targets for pancreatic cancer immunotherapeutics.Chemically synthesized molecules with the targeting and effector functions of antibodies.Protein cell-surface display through in situ enzymatic modification of proteins with a poly(Ethylene glycol)-lipid.Novel agents in indolent lymphomas.Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigenCorrection to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
P2860
Q28658712-BDE6E5FB-71C1-4679-8DE0-AAEFF7064166Q33565265-F5F95B76-F081-405A-87F8-DB791D4F837CQ33619979-3398E21E-0DF1-4447-AD44-5916BCC934D9Q35969904-D1057F28-BC30-4E49-A02E-F8EF8239829EQ36216991-E8B35778-E6B0-4624-A236-020B5CFFC27AQ36485273-75FA402F-AF81-40EC-862C-26666BB962BBQ37148735-464415E8-250B-414A-A505-828FAF1ADB0BQ37364355-FC9967E2-D40C-430C-AA36-7089BA3A967DQ37741534-35A728CF-971D-4997-A3A2-0DB1BFC58BE4Q37852003-2E1B3D2C-9A87-44C1-9037-451954B36166Q37861220-2FF4FD1F-EC52-40E2-8047-C3B0F636C354Q38928032-AC376A02-7062-4444-A12F-B011CFA49445Q39165087-91371A94-365F-4113-8693-071FF8ECFBDCQ39431412-74E30BC9-2B57-40A6-A51C-81AC6FEBFDDBQ42060421-A867C0B6-5F43-4EBF-A8D1-E2C0840BE345Q47193015-8F26F999-D029-4FD9-BC4E-45A95E3DACE6
P2860
Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Humanised IgG1 antibody varian ...... cytotoxicity and phagocytosis.
@en
Humanised IgG1 antibody varian ...... cytotoxicity and phagocytosis.
@nl
type
label
Humanised IgG1 antibody varian ...... cytotoxicity and phagocytosis.
@en
Humanised IgG1 antibody varian ...... cytotoxicity and phagocytosis.
@nl
prefLabel
Humanised IgG1 antibody varian ...... cytotoxicity and phagocytosis.
@en
Humanised IgG1 antibody varian ...... cytotoxicity and phagocytosis.
@nl
P2093
P2860
P921
P356
P1476
Humanised IgG1 antibody varian ...... cytotoxicity and phagocytosis.
@en
P2093
J L Wilding
N J Mortensen
S Q Ashraf
T Ntouroupi
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605355
P407
P577
2009-11-01T00:00:00Z